- Conditions
- Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–62
of 62
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Treatment Resistant Depression
- Interventions
- CERC-501, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
- Conditions
- Treatment-Resistant Depression
- Interventions
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
- Conditions
- Depression
- Interventions
- Naltrexone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Major Depression
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
- Conditions
- Depression
- Interventions
- Brexpiprazole, Ketamine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Garden Grove, California • Oakland, California • Chicago, Illinois + 3 more
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder
- Interventions
- AXS-05, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Ketamine, Placebo Midazolam
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine, placebo
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
- Interventions
- SCC DBS
- Device
- Lead sponsor
- Paul Holtzheimer
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
- Interventions
- Spaced Transcranial Direct Current Stimulation (tDCS), Sham Spaced tDCS
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Treatment Resistant Depression (TRD)
- Interventions
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Drug
- Lead sponsor
- Soterix Medical
- Industry
- Eligibility
- 18 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment Resistant Depression
- Interventions
- MK-1942, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
- Interventions
- electroconvulsive therapy (ECT), Ketamine
- Procedure · Drug
- Lead sponsor
- Bo Hu
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • New York, New York + 2 more